Remove 2020 Remove IPO Remove Valuation
article thumbnail

Okay, which analyzes engineers’ productivity, sells to Stripe

TechCrunch: M&A

Founded in 2019, Okay participated in Y Combinator’s Winter 2020 cohort before going on to raise a total of $6.6 They were u sually companies in the pre-IPO phase with hundreds to thousands of engineers where the manager wanted to start tracking what others are doing, and looking for tools to help with decision-making.”

article thumbnail

Will There Be an IPO for a Specialty Consulting Company in 2024?

Focus Investment Banking

In that environment, very few firms sought IPOs, and there was a major slowdown in overall exits, whether private or public. And will that mean that some of the privately held management consulting firms or other professional services companies will choose an IPO this year? But those companies have been public for more than 20 years.

IPO 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Covid-19 and US Venture Capital in 2020

InvestmentBank.com

One could likely dedicate an entire history book to all that has happened in 2020. This new world has forced many new adaptations and innovations, but what has this meant for those in VC who circled themselves around new trends and innovations long before 2020? According to analysis from PwC and CB Insights, Q2 2020 showed a 9.6%

Capital 40
article thumbnail

Past Event: SPACs: The Next Gen IPO or Just a Fad?

Cooley M&A

Market volatility, a low interest rate environment and disillusionment with the IPO process, have made SPACs an attractive alternative for private companies looking to go public in recent months. According to Odeon Capital Group research, as of December 2, 2020, 210 SPAC IPOs had been completed representing gross proceeds of ~$72 billion.

IPO 52
article thumbnail

Cooley’s 2020 Tech M&A Year in Review

Cooley M&A

While we continue to absorb and understand the worldwide pandemic shockwaves of 2020, trying to encapsulate the vicissitudes of the past year in an annual recap is daunting. 1] The robust momentum in the second half of the year nearly made up for early pandemic effects as 2020 deal value was down only 6.6% A Tale of Two Years.

M&A 40
article thumbnail

Cooley’s 2020 Life Sciences M&A Year in Review

Cooley M&A

If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. Also impacted was Thermo Fisher’s attempted acquisition of Qiagen through a tender offer launched on March 3, 2020.

M&A 40
article thumbnail

Highlights from Cooley’s M&A Dealmakers Roundtable: SPACs!

Cooley M&A

is the increased frequency at which SPAC IPOs are occurring. As reflected in Chart 1 , 102 SPAC IPOs have been announced this year as of September 18, 2020—almost double the number of SPAC IPOs in all of last year (and more than double the number of SPAC IPOs in 2018). SPAC vs. IPO. Valuation Certainty.

M&A 52